Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy

Échec de l'ajout au panier.

Veuillez réessayer plus tard

Échec de l'ajout à la liste d'envies.

Veuillez réessayer plus tard

Échec de la suppression de la liste d’envies.

Veuillez réessayer plus tard

Échec du suivi du balado

Ne plus suivre le balado a échoué

Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

In this podcast accompanying the October issue of DTB (https://dtb.bmj.com/content/63/10) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice (https://dtb.bmj.com/content/63/10/146). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout (https://dtb.bmj.com/content/63/10/147). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (https://dtb.bmj.com/content/63/10/150). Links GP Evidence: https://gpevidence.org/ Preventing Overdiagnosis 2025 International Conference: https://www.cebm.ox.ac.uk/preventing-overdiagnosis Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

Pas encore de commentaire